Micreos appoints Matt Regan as CEO of pharma business

Dutch biotechnology company Micreos has recruited Matt Regan as CEO of its new pharmaceutical business that will be based in Switzerland. Management says following rapid growth, Micreos is preparing to spin out its pharmaceutical business into a separate company as of January 2022 to directly access the capital markets. They add that this will help to fund pipeline development to progress its highly innovative, targeted antibacterial technology platform into pharmaceutical solutions that can improve patient care.

Regan joins Micreos with extensive biopharmaceutical experience from almost three decades working with global healthcare leaders including Abbott, Novo Nordisk, and AbbVie. He has extensive experience across the entire value chain from Manufacturing to Commercial operations and has lived and worked in seven different countries.

Micreos executives add that Regan brings strategic and operational leadership experience to the company while also deeply understanding the needs of healthcare systems to address unmet medical needs.

“I am greatly looking forward to joining the Micreos team and its many talented employees in this important mission of developing viable alternatives to traditional antibiotics,” Regan says. “This is extremely important for patients – but also for healthcare systems around the world who are very concerned about antimicrobial resistance.”

“It’s fantastic to welcome Matt to Micreos,” says Mark Offerhaus, founder and CEO of Micreos. “Matt shares our values and the determination to take our technology to the next level. Challenging the way chronic inflammation is currently treated, we aim to open up new ways to help millions of people around the world.”